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1. Introduction
The presence of an obstruction in the outflow tract of the right ventricle (RV) consists of a
relatively common defect, present in 20% to 30% of cyanotic congenital heart diseases. The
extreme degree of pulmonary obstruction is pulmonary atresia (anatomical discontinuity
between RV - Pulmonary Artery), present in approximately 5% of patients with heart defects.
In these situations, surgical treatment may require the use of a prosthesis or implantation of a
valved conduit to reconstruct the pulmonary valve and outflow tract of the RV. Different valve
replacements have been proposed, including the fresh aortic homografts, pulmonary hetero‐
grafts, pig or bovine pericardial prostheses. Amongst the valved conduits we have: bovine
pericardial grafts, porcine pulmonary graft, bovine jugular containing Dacron prostheses,
aortic homograft, or more recently, pulmonary homografts. Mechanical prostheses were
virtually abandoned. Whichever type of replacement valve used, many studies have reported
calcification or tissue degeneration associated to pseudo-intimal proliferation and progressive
obstruction of the conduit [1], [2], [3], [4], [5] with the need for reoperation, the incidence of
which may vary between 14% and 30% at 5 years and 32% to 100% at 10 years. [4], [5], [6], [7],
[8] In 1991, we began a new experience in the Cardiovascular Division of the Federal University
of São Paulo (Unifesp), using 2 models of biological prostheses: heterografts (swine) treated
with glutaraldehyde and formaldehyde [9], adding in recent years other 2 models. These 4
different prostheses were implanted in 203 children with heart defects that required recon‐
struction of the pulmonary valve and right ventricular outflow tract. [10] The late outcome of
these patients is represented by actuarial Kaplan & Meier curve: The survival of these patients
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was 86.6% operated and free reoperations in 68.3% of cases, in 180 months of median rate of
follow-up. (Figure 1 ) The most frequent cause of reoperations was calcification, tissue
degeneration and loss of function due to growth of the patient.
The implantation of a bioprosthetic porcine valve in a patient, is considered as a form of living
tissue transplantation. Xenotransplantation, which usually has a very aggressive form of
rejection by the immune system of the patient. Aiming to reduce this type of immunogenicity,
bioprostheses are fixed in glutaraldehyde solution, with the intention of transforming the
tissue graft immunologically inert.
However, bioprostheses that were fixed in glutaraldehyde also have the propensity to calcify.
This calcification is a major contributor for dysfunction of cardiac bioprostheses due to the pre-
treatment of biological tissue with glutaraldehyde to devitalize the cells ceasing residual cells
that become the primary sites for deposition of calcium phosphate. The reaction of calcium
with the extracellular fluid associated with the reactions of phosphorus to the cell membrane
causes pathological calcification of bioprostheses.
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Figure 1. Actuarial curve of patients undergoing reconstruction of the pulmonary valve and outflow tract of the right
ventricle with pulmonary heterograft. (Miguel Maluf, The Heart Surgery Forum 2011; 14 (1): E40-50.
Despite the deterioration of the heterograft keeps the order of 35% to 45% in 15 and 20 years,
respectively. There are always isolated cases with long postoperative course, without com‐
promising tissue or calcification of porcine bioprostheses. [11].
During the last decade there was an excellent immediate biocompatibility of polycarbonour‐
ethane valves (PCU) used in temporary ventricular assistance. [12] Although the follow-up in
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this group of patients is quite short, low rates of thromboembolic complications and no failures
or calcification have been documented. Such valves were implanted experimentally, replacing
heart valves and satisfactory results in long-term left ventricular assistance devices in between
the apex of the left ventricle and the aorta. [13] Furthermore, the replacement valve is used in
a next generation of total artificial heart implants. [14] However, the intermediate result of
such artificial valves, when the prosthesis is implanted on the right side of the heart, exposed
to low pressure and low levels of oxygen saturation, the prosthesis would have increased
durability. The segmented polyurethanes (SPUs) are a class of versatile material possessing
various controllable properties. This unique feature can make them advantageous for use as
biomaterials, structural materials and other applications.
More than 50 years of research has been devoted to this area, which led to an understanding
of the synthesis, structure and properties of these fascinating materials. In general, the SPUs
have a structure comprising a macrodiol "soft" segment (SS) and urethane "hard" segment (SH),
each segment has an incompatible composition with the separation of different phase driving
nanoscale domains which control properties of SPUs. It is believed that HSS, glassy or
crystalline, has the melting temperature (Tm) above room temperature. Forman domains are
on the order of a few tens of nanometers. These domains SSs, are difficult to separate and are
generally formed at low temperature to the glass transition (Tg) of amorphous to crystalline.
2. Objectives of research
The objectives of this study are:
To build a heart prosthesis of segmented polyurethane (SPU)
2.1. Methods
a. Drawing in 3D of a human aortic valve, obtained from an examination of Angio-Compu‐
terized Tomography (Angio-CT)
b. Matrix of the prosthesis.
c. Prepare of segmented polyurethane (SPU).
d. Manufacture of prosthesis by injection of SPU in the matrix.
2.2. Building a model of segmented Polyurethane (SPU) prosthesis
a. Design of the prosthesis in 3 D and Manufacturing of Moulds:
The 3-D drawing for manufacturing of the polyurethane was based on anatomical characteristics
of Angio-CT of the human aortic and pulmonary valve.
We considered internal and external diameter, shape of the ring and stem where they operate
the valve leaflets.
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The valve leaflets were preserved, an angle of 120° from the place of central coaptation to the
base of the valve ring deployment. Each leaflet has a thickness in the central region of the free
edge of 0.2 mm and 0.5 mm in the rest of the extension. The program to be used for the design
of this prosthesis is generated by Solid Works software, the computer program generates mesh
and solid parametric.
Figure 2. Angio Computerized Tomography (Angio-TC) of a human Aortic Valve
• Modeling of the Ring and Membrane
From pre-established dimensions by Angio-CT, the software was modeled using the ring and
the membranes of the 3 cusps. figures 2,3,4
• Drawing of the Ring
Figure 3. Drawing of a prosthetic ring
Figure 4. Drawing of three leaflets of the membrane, with the prosthetic ring
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b. Making the Matrix
The array was fabricated on a machine called "Vertical Machining Center". It is nothing more
than a machine tool with computer numerical control. Utilizing cutting tool, and stainless steel
plant directly. Figures: 5,6,7
Figure 5. Matrix made of stainless steel
Figure 6. Coupling ring in the matrix and stainless steel support
Figure 7. Coupling of the matrix to the ring and support for the filling with segmented polyurethane (SPU)
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c. Manufacturing segmented polyurethane prostheses
Among the polymeric materials used in clinical practice, polyurethanes have paved their place
in the market and are the best choice for application in the field of medical implants. Present
biostability, biocompatibility, high lubricity, strength, abrasion resistance and fatigue is also
easy to use, presenting flexibility and resistance to thromboembolism. These are some of the
reasons why polyurethanes are used for a variety of medical devices. To develop a prosthetic
heart it will be necessary to use a polymer that has the characteristics described above, it is
necessary hemodynamic and biophysical testing to rate the quality of the material.
• Polyurethanes
Thermoplastic polyurethanes exhibit a wide range of technological applications due to the
versatility of the chemical structure and properties that can be achieved from various com‐
mercially available diisocyanates and alkanediols. Additionally, the physical properties achiev‐
able in these materials can be enlarged by the relative concentrations of the raw materials
capable of producing polymers.
The polyurethanes exhibit microphase separated structure comprising soft segments and hard
segments.  The flexible segments are formed usually from oligomers with long segments
such as methylene, oxy-alkylene, or other aliphatic sequence, while the hard segment is formed
by urethanic  segments  resulting from the reaction of  short  chain alkanediols  and diisocya‐
nates. The highly polar nature of the urethane linkages is responsible for the thermodynam‐
ics  of  phase  separation  micro-heterogeneous,  which  together  with  the  possibility  of
formation of crystalline phase in the hard and soft phases, make complex relations between
these various domains and the physical and mechanical behavior observed. Additionally,
it  is  noted that  the formation of  these domains in  polyurethanes  is  also a  function of  its
processing,  since,  in  general,  the  thermodynamic  equilibrium  is  not  achieved  in  these
materials during their transformation process.  In order to ensure consistent performance
of the product it is essential that its microstructure does not change significantly with time.
Thus,  for  applications  with  high  demands  is  the  use  of  appropriate  heat  treatment,
annealing, and the environmental application similar to the use of the product, where in
contact  with  blood,  subjected  to  cyclic  strain.  It  is  noteworthy that  the  use  of  dynamic
mechanical thermal analysis allows detailed tracking of transformations undergone by the
product according to the process of thermal annealing and contact with fluid.
d. Manufacturing prostheses by injection of PCU matrix
In this design, it is intended to prepare polyurethane membranes from different sources using
the techniques of hot pressing and evaporation of the solution. Prepare membranes with
different thicknesses in the range of 50 to 200 um. These membranes are subjected to thermal
annealing treatments in idealized fluids simulating blood.
The membranes obtained under different conditions are identified, using the techniques of X-
ray diffractometry, differential scanning calorimetry and dynamic mechanical thermal
analysis, among others. Additionally, ultrasound technique allows the analysis for the
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presence of defects in 100% of the membranes to be employed in the construction of prosthetic
heart polyurethane. Figure 8.
 
Figure 8. Prototype of Segmented Polyurethane(SPU) prosthesis.
3. Discussion
3.1. Durability of polyurethane prosthesis tested “in vitro”
The SPU prostheses have shown a useful life of over 130 million cycles in real time and 420
million cycles at accelerated conditions without failure of the SPU [13]. In vivo conditions, the
longest period after implantation was 399 days, performing euthanasia due to the excessive
growth of the animal. [13] In summary, these data demonstrate the good hemodynamic
performance behavior of the implanted SPU prosthesis right side of the heart, in particular
lack of a significant pressure gradient after 1 year of implantation. This study confirms the
good biocompatibility of SPU (low thrombogenicity in animals without anticoagulant therapy)
and short-term durability of such compounds without the use of anti-calcification in a model
of accelerated mineralization.
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